Risk factors for systemic and venous thromboembolism, mortality and bleeding risks in 1125 patients with COVID-19: relationship with anticoagulation status1125명의 COVID-19 환자에서 전신 및 정맥 혈전색전증, 사망률 및 출혈 위험에 대한 위험 요소: 항응고 상태와의 관계Research Paper Published on 2021-04-152022-09-10 Journal: Aging (Albany NY) [Category] SARS, 치료제, [키워드] 95% confidence interval age Anticoagulants anticoagulation Antithrombotic antiviral drugs bleeding bleeding event bleeding events China Chinese Comorbidities coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection COVID-19 patients Cox proportional hazard models death determine drug therapies drugs enrolled events Factor Follow-up hazard ratio high risk hospitalized patient hospitalized patients immunomodulators increased mortality independent risk factor Infection liver dysfunction lymphocyte Lymphocyte count major bleeding morbidity Mortality outcome Patient predicted Prevalence reduced Retrospective study risk risk factor severity of COVID-19 significantly Standard deviation suffered surgery Therapies thromboembolic thromboembolic and bleeding events Thromboembolism Union Hospital Venous Thromboembolism with COVID-19 Wuhan [DOI] 10.18632/aging.202769 PMC 바로가기 [Article Type] Research Paper
Association of Clinical, Biological, and Brain Magnetic Resonance Imaging Findings With Electroencephalographic Findings for Patients With COVID-19코로나19 환자를 위한 뇌파 검사 소견과 임상, 생물학 및 뇌 자기 공명 영상 소견의 연관성Research Published on 2021-03-152022-09-10 Journal: JAMA Network Open [Category] SARS, 치료기술, [키워드] Abnormalities activities acute respiratory syndrome acute respiratory syndrome coronavirus age analyses Analysis analyzed association awakening Biological biological abnormalities Brain brain MRI Can Central nervous system cerebrospinal fluid Chain Reaction Chest clinical Clinical management cohort of patient cohort study Computed tomography conducted coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 defined delayed awakening delirium detection diagnose Diagnosis disorders Dysnatremia Electroencephalography Electronic patient records Encephalopathy enrolled epileptic events Evidence evidence of exposure feature Features finding France had no help heterogeneous Hospitalization Hospitalized identify imaging impairment Importance indication Infection Injury intensive care intensive care unit ischemic lesions kidney Kidney failure lesions liver dysfunction magnetic resonance imaging Manifestations measure men Movement disorders MRI nasopharyngeal specimen neurologic nonspecific objective Paris participant pathologic Patient patient records patients patients with COVID-19 Pneumonia Point Relevance resonance respiratory Result retrieved retrospective cohort study reverse transcription SARS-CoV-2 Seizure setting severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 syndrome tested Treatment White matter with COVID-19 [DOI] 10.1001/jamanetworkopen.2021.1489 PMC 바로가기 [Article Type] Research
Severe liver dysfunction complicating course of COVID-19 in the critically ill: multifactorial cause or direct viral effect?Research Published on 2021-03-152022-10-28 Journal: Annals of Intensive Care [Category] COVID-19, [키워드] 95% CI admitted to ICU age analyzed caused Characteristics Cholestatic liver disease clinical Clinical characteristics Comorbidity confounders contribute coronavirus disease Course COVID-19 Critically ill Critically ill patient defined ECMO evaluated Gender had more Health high mortality Hypoxic liver injury ICU in both groups jaundice Laboratory liver dysfunction Liver injury mechanical ventilation Mortality multifactorial Occurrence outcome overlapped pandemic Patient Presence renal replacement therapy reported required Result SARS-CoV-2 severe respiratory failure severity severity of illness significantly higher supplementary material therapy ULN university hospital Viremia with COVID-19 [DOI] 10.1186/s13613-021-00835-3 PMC 바로가기 [Article Type] Research
COVID-19 in Children With Liver DiseasePediatrics Published on 2021-03-112022-10-31 Journal: Frontiers in Pediatrics [Category] COVID-19, [키워드] Adults association asymptomatic infection Autoimmune Care caused children chronic conditions chronic liver disease CLD Clinical course Complication component concerning COVID-19 COVID-19 infection COVID-19 patients database disease evaluate General population global pandemic Health healthy highlight hypoxia Immunosuppressed immunosuppressive Immunosuppressive medication Immunosuppressive treatment increased risk infected with COVID-19 literature review liver cells Liver disease liver dysfunction Liver injury Liver transplantation maintain majority medication Mild multicenter National outbreak Patient preserved Prevent rejection remained reported required Research resulting SARS-CoV-2 SARS-CoV-2 disease SARS-COV-2 infection severe disease course transaminases viral infection was performed with COVID-19 [DOI] 10.3389/fped.2021.616381 PMC 바로가기 [Article Type] Pediatrics
Digestive system involvement of infections with SARS-CoV-2 and other coronaviruses: Clinical manifestations and potential mechanismsReview Published on 2021-02-212023-06-15 Journal: World journal of gastroenterology [Category] MERS, [키워드] coronavirus COVID-19 Gastrointestinal diseases liver dysfunction mechanisms SARS-CoV-2 [DOI] 10.3748/wjg.v27.i7.561 PMC 바로가기 [Article Type] Review
Hepatotropic Properties of SARS-CoV-2—Preliminary Results of Cross-Sectional Observational Study from the First Wave COVID-19 PandemicArticle Published on 2021-02-092022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] affected alanine aminotransferase albumin ALP ALT ALT/AST analyzed Aspartate aminotransferase AST characteristic clinical Comorbidity contribute COVID-19 COVID-19 disease Cytopathic effect drug elevated expressed feature Frequency Hepatitis hepatocyte hepatocytes hepatotoxic Hospitalized hypoxia Immune-mediated Inflammatory response Injury laboratory parameter less liver Liver damage liver dysfunction liver enzyme liver enzyme abnormality Liver function Mild parameter parameters Patient patients hospitalized patients with COVID-19 potential mechanism property Result SARS-CoV-2 SARS-COV-2 infection transpeptidase Wave were excluded [DOI] 10.3390/jcm10040672 PMC 바로가기 [Article Type] Article
Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19COVID-19 환자에서 favipiravir에 의해 유발된 담즙정체성 간 손상 의심Case Reports Published on 2021-02-012022-09-11 Journal: Journal of infection and chemotherapy : official j [Category] SARS, 치료제, [키워드] addition Administered alcoholic hepatitis Antibiotics Antimicrobial therapy antiviral drug Bacterial bacterial pneumonia Bilirubin Cholestasic Complication Deterioration drug therapy elevated expected extracorporeal membrane oxygenation Favipiravir Hepatitis High dose Hyperuricemia impaired liver function interferon Japanese liver dysfunction Liver function Liver injury Lopinavir Lopinavir/ritonavir monitoring Patient patient with COVID-19 Pneumonia promoted Ritonavir SARS-CoV2 SARS-CoV2 infection Side effect Side effects subsequent Support Suspected teratogenicity therapeutic effect total bilirubin transaminase Treatment triggered veno-venous extracorporeal membrane oxygenation worsened [DOI] 10.1016/j.jiac.2020.12.021 PMC 바로가기 [Article Type] Case Reports
The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage inducedReview Published on 2021-01-272022-10-31 Journal: Egyptian Liver Journal [Category] COVID-19, [키워드] ACE-2 addition Administered Antiviral caused cells cellular Clinical management COVID-19 COVID-19 patient COVID-19-SARS-CoV-2 deaths diabetes disease drug drug treatments effective enzyme Evidence example global pandemic Host hypertension Infection Inflammation last stage liver liver cholangiocytes Liver damage Liver disease liver dysfunction Liver fibrosis Liver injury liver tissue manuscript mechanism Mortality mortality rate new coronavirus SARS-CoV-2 Obeticholic acid occur pandemic Patient penetration pharmacological management Prevent recent receptor reduce reducing risk risk factor SARS-CoV-2 severe COVID-19 severity of COVID-19 shown Singapore stages those with comorbidity type II pneumocytes Vaccine Vaccines viral entry virus [DOI] 10.1186/s43066-021-00082-y PMC 바로가기 [Article Type] Review
Clinical characteristics of 14 COVID-19 deaths in Tianmen, China: a single-center retrospective studyResearch Article Published on 2021-01-202022-10-28 Journal: BMC Infectious Diseases [Category] COVID-19, MERS, [키워드] Acute kidney injury acute respiratory distress Admission age analyzed ARDS C-reactive protein cardiovascular disease Characteristics Chest CT chronic disease Chronic kidney disease clinical Clinical characteristics Comorbidities cough COVID-19 Critically ill patient CRP death deaths died Dyspnea elderly elevated epidemiological evaluated Factors Fever General symptom had more healthcare high risk Hospitalized hypertension increased risk Injury IQR Laboratory liver dysfunction lymphocyte median men Most patient Older onset of symptom organ dysfunction Patient radiological reduced Region reported resource Result Retrospective study SARS-CoV-2 SARS-CoV-2-infected patient severe pulmonary lesions significantly single-center supplementary material symptomatic syndrome the median Treatment with COVID-19 Wuhan [DOI] 10.1186/s12879-021-05770-z PMC 바로가기 [Article Type] Research Article
A structured summary of a study protocol for a multi-center, randomized controlled trial (RCT) of COVID-19 prevention with Kampo medicines (Integrative Management in Japan for Epidemic Disease by prophylactic study: IMJEDI P1 study)Kampo 의약품을 사용한 COVID-19 예방에 대한 다기관, 무작위 대조 시험(RCT) 연구 프로토콜의 구조화된 요약(예방 연구에 의한 전염병에 대한 일본의 통합 관리: IMJEDI P1 연구)Letter Published on 2021-01-062022-08-31 Journal: Trials [Category] MERS, 임상, 치료제, [키워드] 1:1 administration age allergic Analysis appearance Arm ARMS assumed Asymptomatic balancing Blinding body temperature calculated capture cardiovascular disease Chain Reaction clinical clinical trials cloud condition Control control group cough COVID-19 diabetes disappearance dissemination doctor dosage dropout rate drug edema effective element Endpoint exclusion criteria failure Fever Final final analysis final analysis) Frequency group hands healthy history hospital Hospitalization hypertension hypokalaemia Hypothesis ICU Immunosuppressant immunosuppressants incidence of COVID-19 incidence rate incidence rates include inclusion criteria Infection infection rate Inflammation interim analysis interstitial pneumonia intervention group investigator Japan Japanese Kampo Kampo medicines liver dysfunction lung malaise management mechanical ventilation Medicine number numbness objective observation period oral administration oral administration) outcome package parallel-group participant Patient PCR PCR positive per day Period pharmaceutical Placebo placebo group Placebo tablets positive result power power of 80% pregnant Prevent Prophylactic prophylactic study protocol randomised Randomized Randomized controlled trial RCT receive recruited Registered Registration registry required Research respiratory respiratory diseases respiratory inflammation risk factor Risk factors Safety Sample size SARS-CoV-2 RNA secondary Secondary outcomes Shock Shortness of breath significantly skin rash sputum study drug study period Study protocol supplementary material Symptom Symptoms symptoms of COVID-19 Tablet Taking Taste the placebo group Trial Trial registration Two-arm university upper respiratory verification Viral viral infection Vital website [DOI] 10.1186/s13063-020-04939-2 PMC 바로가기 [Article Type] Letter